loading page

High grade B-cell lymphoma developed in the course of chronic myeloid leukemia treatment with bosutinib
  • +7
  • Teruhito Takakuwa,
  • Ryota Sakai,
  • Shiro Koh,
  • Hiroshi Okamura,
  • Satoru Nanno,
  • Yasuhiro Nakashima,
  • Takahiko Nakane,
  • Hideo Koh,
  • Masayuki Hino,
  • Hirohisa Nakamae
Teruhito Takakuwa
Osaka City University Graduate School of Medicine School of Medicine
Author Profile
Ryota Sakai
Osaka City University Graduate School of Medicine School of Medicine
Author Profile
Shiro Koh
Osaka City University Graduate School of Medicine School of Medicine
Author Profile
Hiroshi Okamura
Osaka City University Graduate School of Medicine School of Medicine
Author Profile
Satoru Nanno
Osaka City University Graduate School of Medicine School of Medicine
Author Profile
Yasuhiro Nakashima
Osaka City University Graduate School of Medicine School of Medicine
Author Profile
Takahiko Nakane
Osaka City University Graduate School of Medicine School of Medicine
Author Profile
Hideo Koh
Osaka City University Graduate School of Medicine School of Medicine
Author Profile
Masayuki Hino
Osaka City University Graduate School of Medicine School of Medicine
Author Profile
Hirohisa Nakamae
Osaka City University Graduate School of Medicine
Author Profile

Abstract

The 75-year-old male patient had been diagnosed with CML 25 years ago. Over 3 years after starting bosutinib, he was diagnosed with a HGBCL. A total of six courses of DA-EPOCH-R therapy brought complete remission of the lymphoma. Eight months after stopping bosutinib, BCR-ABL1 transcript copies remained undetectable by RT-PCR.

Peer review status:ACCEPTED

26 May 2020Submitted to Clinical Case Reports
27 May 2020Submission Checks Completed
27 May 2020Assigned to Editor
13 Jun 2020Reviewer(s) Assigned
04 Jul 2020Review(s) Completed, Editorial Evaluation Pending
12 Aug 2020Editorial Decision: Revise Minor
29 Nov 20201st Revision Received
11 Dec 2020Submission Checks Completed
11 Dec 2020Assigned to Editor
11 Dec 2020Review(s) Completed, Editorial Evaluation Pending
17 Dec 2020Editorial Decision: Accept